Carbapenems play a significant role in the current antibiotic armamentarium. Doripenem is
the newest carbapenem to be commercially released. Its antimicrobial spectrum more …

Evaluation of the in vitro interaction of doripenem and amikacin against Acinetobacter
baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae was done by classifying …

Background Bacterial resistance presents a constant challenge in the treatment of
hospitalized patients, particularly with Gram-negative infections. Carbapenems have an …

The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to
determine the in vitro potency of doripenem compared with imipenem and meropenem …

Aims: The aim of this study was to evaluate the in vitro activity of doripenem (DOR) alone
and in combination with a variety of commonly used anti-Acinetobacter chemotherapeutic …

PURPOSE: Doripenem is an investigational carbapenem with potent activity against
bacterial pathogens commonly responsible for nosocomial pneumonia (NP), including …

The doripenem MICs at which 90% of the tested strains were inhibited ranged from 0.03 to 1
μg/ml for 10 species of Enterobacteriaceae (n= 351), from 0.03 to 0.12 μg/ml for oxacillin …

Difficult-to-treat infections caused by gram-negative pathogens are common in the hospital
setting, particularly those caused by Pseudomonas aeruginosa, Acinetobacter species, and …

Doripenem (DPM) is the newest antimicrobial in the carbapenem class. It is a broad
spectrum agent with activity against gram-positive, gram-negative and anaerobic bacteria. in …

Background Doripenem is the most recently introduced antimicrobial agent of the
carbapenem class. It is a valuable therapeutic option in the context of increasing …